Table 3 The SMR analysis results of exposures and outcomes
From: Therapeutic Targets for Gastric Cancer: Mendelian Randomization and Colocalization Analysis
Exposure | Outcome | P_SMR(5e-8) | P_HEIDI |
|---|---|---|---|
ANGPT2 | Gastric Cancer | 0.268602 | 0.716771 |
ATRAID | Gastric Cancer | 0.125384 | 0.711295 |
CD6 | Gastric Cancer | 0.061689 | 0.019478 |
CPQ | Gastric Cancer | 0.058328 | 0.264361 |
FUT8 | Gastric Cancer | 0.41998 | 0.044049 |
HCG22 | Gastric Cancer | 0.007043 | 7.99E-05 |
IGLC2 | Gastric Cancer | 0.059307 | 0.5035 |
LILRB1 | Gastric Cancer | 0.259936 | 0.411092 |
LTB | Gastric Cancer | 0.410333 | 0.502017 |
PPCDC | Gastric Cancer | 0.015257 | 0.017729 |
RGMA | Gastric Cancer | 0.222759 | 0.488385 |
TLR3 | Gastric Cancer | 0.517418 | 0.590523 |
TNFRSF10C | Gastric Cancer | 0.030152 | 0.888369 |
TNFRSF11A | Gastric Cancer | 0.551075 | 0.969323 |
TNFSF12 | Gastric Cancer | 0.902046 | 0.533419 |